We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Approves AstraZeneca’s Iressa for First-Line Treatment of Metastatic Lung Cancer
FDA Approves AstraZeneca’s Iressa for First-Line Treatment of Metastatic Lung Cancer
AstraZeneca’s kinase inhibitor Iressa received FDA approval Monday as the first and only first-line treatment for patients with metastatic non-small cell lung cancer whose tumors have certain types of gene mutations, along with a companion diagnostic.